Table 1 Clinical and pathological characteristics of the study cohort
Patients, n = 33 | Value |
|---|---|
Age (years) | Â |
 Median | 70 |
 Range | 53-82 |
ECOG performance status, n (%) | Â |
 0 | 23 (69.6) |
 1 | 5 (15.2) |
 2 | 5 (15.2) |
Gleason score at diagnosis, n (%) | Â |
 Unknown | 3 (9.1) |
  ≤ 7 | 11 (33.3) |
  ≥ 8 | 19 (57.6) |
Primary therapy, n (%) | Â |
 RP | 9 (27.3) |
 EBRT | 4 (12.1) |
 Palliative | 20 (60.6) |
Metastatic sites, n (%) | Â |
 Soft tissue | 3 (9.0) |
 Bone + LN | 15 (45.5) |
 Bone + Visceral ± LN | 15 (45.5) |
Biochemical markersa | Â |
 PSA [ng/dl] | 140 |
0.1-3378 | |
 Lactate dehydrogenase [U/l] | 320 |
218-1900 | |
 Alkaline phosphatase [U/l] | 164 |
50-1466 | |
 Hemoglobin [g/dl] | 11.6 |
8.5-16.1 |